P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
Ehab Atallah,
Michael Mauro,
Koji Sasaki,
Moshe Yair Levy,
Paul Koller,
Islam Sadek,
Daisy Yang,
Julie Ruckel-Kumar,
Mahmudul Khan,
Jorge Cortes
Affiliations
Ehab Atallah
1 Medical College of Wisconsin, Milwaukee, United States
Michael Mauro
2 Memorial Sloan Kettering Cancer Center, New York, United States
Koji Sasaki
3 The University of Texas MD Anderson Cancer Center, Houston, United States
Moshe Yair Levy
4 Baylor Scott & White Health, Dallas, United States
Paul Koller
5 City of Hope National Medical Center, Duarte, United States
Islam Sadek
6 Novartis Pharmaceuticals Corporation, East Hanover, United States
Daisy Yang
6 Novartis Pharmaceuticals Corporation, East Hanover, United States
Julie Ruckel-Kumar
6 Novartis Pharmaceuticals Corporation, East Hanover, United States
Mahmudul Khan
6 Novartis Pharmaceuticals Corporation, East Hanover, United States
